{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:47Z","timestamp":1788844247203,"version":"build-2803163510"},"reference-count":75,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a disorder of hepatic lipid metabolic reprogramming rather than a consequence of passive triglyceride accumulation. Chronic nutrient excess, insulin resistance, adipose tissue dysfunction, and altered nutrient-sensing pathways disrupt the balance among hepatic fatty acid uptake, de novo lipogenesis, \u03b2-oxidation, lipid storage, and lipoprotein export. These changes promote the accumulation of bioactive lipid species, including saturated fatty acids, ceramides, diacylglycerols, oxidized phospholipids, and free cholesterol. Unlike triglycerides, which may serve an adaptive buffering role under conditions of preserved lipid-storage capacity, these bioactive lipids function as metabolic stress signals that impair insulin signaling, disrupt mitochondrial and endoplasmic reticulum homeostasis, activate PKC, JNK, MAPK, NF-\u03baB, and NLRP3 pathways, and promote hepatocyte death, immune activation, and fibrogenesis. Emerging lipidomic and multi-omic approaches further demonstrate that the molecular composition and subcellular distribution of hepatic lipids may be more closely associated with disease progression than total lipid content. This review critically integrates current evidence on hepatic lipid metabolic reprogramming, lipid-mediated signaling, organelle dysfunction, fibrosis, and molecular heterogeneity in MASLD. It also evaluates the translational potential and limitations of lipidomic biomarkers and mechanism-based therapies targeting lipogenesis, nuclear receptors, ceramide metabolism, inflammatory signaling, and fibrosis. A deeper understanding of disease-specific lipid signatures and signaling networks may support molecular endotyping, mechanism-based therapeutic strategies, and precision hepatology in patients with metabolic dysfunction-associated steatohepatitis (MASH) and progressive fibrosis.<\/jats:p>","DOI":"10.3390\/ijms27177805","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities"],"prefix":"10.3390","volume":"27","author":[{"given":"Tatjana","family":"\u00c1bel","sequence":"first","affiliation":[{"name":"Department of Dietetics and Nutritional Sciences, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Csobod Csajb\u00f3kn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dietetics and Nutritional Sciences, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-Analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014Role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccali","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","article-title":"Ceramides in metabolism: Key lipotoxic players","volume":"83","author":"Chaurasia","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: The good, the bad, and the unknown","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Syed-Abdul, M.M. (2024). Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites, 14.","DOI":"10.3390\/metabo14010012"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s44324-024-00022-5","article-title":"Autophagy and hepatic lipid metabolism: Mechanistic insight and therapeutic potential for MASLD","volume":"2","author":"Raza","year":"2024","journal-title":"npj Metab. Health Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., and Peiseler, M. (2022). Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052668"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"20","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00018-022-04401-3","article-title":"Contribution of specific ceramides to obesity-associated metabolic diseases","volume":"79","author":"Hammerschmidt","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cmet.2017.12.003","article-title":"Could ceramides become the new cholesterol?","volume":"27","author":"Summers","year":"2018","journal-title":"Cell Metab."},{"key":"ref_23","first-page":"815","article-title":"Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Minetti, E.T., Hamburg, N.M., and Matsui, R. (2024). Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: The threats of oxidative stress. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1469492"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12944-024-02380-x","article-title":"The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Heymann","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Theocharidou, E., Germanidis, G., and Gika, H. (2024). A comprehensive analysis of liver lipidomics signature in adults with metabolic dysfunction-associated steatohepatitis-a pilot study. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252313067"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101853","DOI":"10.1016\/j.xcrm.2024.101853","article-title":"Metabolomics at the Cutting Edge of Risk Prediction of MASLD","volume":"5","author":"Tan","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","article-title":"Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Beyo\u011flu, D., Popov, Y.V., and Idle, J.R. (2024). Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312809"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: From mechanism to the clinic. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294267"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-024-02092-2","article-title":"Advances in management of metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeutics","volume":"23","author":"Jiang","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s44324-024-00020-7","article-title":"Some paradoxes and unresolved aspects of hepatic de novo lipogenesis","volume":"2","author":"Jones","year":"2024","journal-title":"npj Metab. Health Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MOL.0000000000000983","article-title":"The intracellular chylomicron highway: Novel insights into chylomicron biosynthesis, trafficking, and secretion","volume":"36","author":"Visser","year":"2025","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.jlr.2022.100278","article-title":"An updated perspective on the dual-track model of enterocyte fat metabolism","volume":"63","author":"Cook","year":"2022","journal-title":"J. Lipid Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Zhou, Y., Wang, D., Huang, Z., Xiao, X., Zheng, Q., Li, S., Long, D., and Feng, L. (2023). Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417514"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014A consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCRESAHA.123.323284","article-title":"VLDL biogenesis and secretion: It takes a village","volume":"134","author":"Ginsberg","year":"2024","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ortega-Prieto, P., and Postic, C. (2019). Carbohydrate sensing through the transcription factor ChREBP. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00472"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: Guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bilson, J., Scorletti, E., Swann, J.R., and Byrne, C.D. (2024). Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases. Biomolecules, 14.","DOI":"10.3390\/biom14070841"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00394-024-03560-2","article-title":"The effects of saturated and unsaturated fatty acids on MASLD: A Mendelian randomization analysis and in vivo experiment","volume":"64","author":"Xu","year":"2024","journal-title":"Eur. J. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Pan, Y., Li, J., Lin, P., Wan, L., Qu, Y., Cao, L., and Wang, L. (2024). A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer\u2019s disease, and their co-morbidities. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1348410"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ramos-Molina, B., Rossel, J., P\u00e9rez-Montes de Oca, A., Pardina, E., Genua, I., Rojo-L\u00f3pez, M.I., Juli\u00e1n, M.T., Alonso, N., Julve, J., and Mauricio, D. (2024). Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1400961"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hoebinger, C., Rajcic, D., and Hendrikx, T. (2022). Oxidized lipids: Common immunogenic drivers of non-alcoholic fatty liver disease and atherosclerosis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.824481"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., and Ma, X. (2025). Mitochondrial dysfunction as a pathogenesis and therapeutic strategy for metabolic-dysfunction-associated steatotic Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094256"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101774","DOI":"10.1016\/j.aohep.2024.101774","article-title":"Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Mu","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction\u2013associated steatotic liver disease (MASLD) Pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ma, Y., Lee, G., Heo, S.-Y., and Roh, Y.S. (2022). Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxidants, 11.","DOI":"10.3390\/antiox11010091"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2019.01.026","article-title":"Autophagy in liver diseases: Time for translation?","volume":"70","author":"Allaire","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ma, X., McKeen, T., Zhang, J., and Ding, W.-X. (2020). Role and mechanisms of mitophagy in liver diseases. Cells, 9.","DOI":"10.3390\/cells9040837"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jee, Y.-M., Lee, J.-Y., and Ryu, T. (2025). Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: From steatosis to hepatocellular carcinoma. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051260"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.jhepr.2024.101196","article-title":"Understanding the complex macrophage landscape in MASLD","volume":"6","author":"Liu","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5483\/BMBRep.2024-0058","article-title":"Neutrophils in MASLD and MASH","volume":"58","author":"Shrestha","year":"2025","journal-title":"BMB Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imm.13943","article-title":"The roles of T cells in the development of metabolic dysfunction-associated steatohepatitis","volume":"176","author":"Ge","year":"2025","journal-title":"Immunology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Ren, L., Tian, Y., Guo, X., Wei, F., and Zhang, Y. (2024). Signaling pathways that activate hepatic stellate cells during liver fibrosis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1454980"},{"key":"ref_60","first-page":"goae089","article-title":"Active role of the immune system in metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Mori","year":"2024","journal-title":"Gastroenterol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-\u03b21 signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2016.169","article-title":"Sphingolipids and phospholipids in insulin resistance and related metabolic disorders","volume":"13","author":"Meikle","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/a-2364-2928","article-title":"A precision medicine guided approach to the utilization of biomarkers in MASLD","volume":"44","author":"Thakral","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmsacl.2022.02.002","article-title":"Clinical lipidomics\u2014A community-driven roadmap to translate research into clinical applications","volume":"24","author":"Vvedenskaya","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1194\/jlr.M079012","article-title":"Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950\u2013Metabolites in Frozen Human Plasma","volume":"58","author":"Bowden","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.53388\/ghr2024013","article-title":"Metabolic dysfunction-associated steatotic liver disease: Progress, challenges, and prospects of precision medicine","volume":"6","author":"Zhu","year":"2024","journal-title":"Gastroenterol. Hepatol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): A comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: Where are we today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: A multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cgh.2024.05.021","article-title":"Combination treatment in MASLD: The next Frontier","volume":"23","author":"Tsochatzis","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"119467","DOI":"10.3748\/wjg.119467","article-title":"Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications","volume":"32","author":"Tarantino","year":"2026","journal-title":"World J. Gastroenterol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:28:20Z","timestamp":1788841700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":75,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177805"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177805","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}